ASND vs VRTX
Ascendis Pharma A/S vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
ASND
Ascendis Pharma A/S
66
Buy
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | ASND | VRTX |
|---|
| AI Score |
66
|
66
|
| Price |
$254.27
|
$529.70
|
| P/E Ratio |
26.92×
|
30.58×
|
| ROE |
134.6%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
88.2%
|
86.0%
|
| Debt / Equity |
1.84×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.3
|
80.4
|
| Beta |
0.382
|
0.305
|
| Expected Upside |
—
|
+1.5%
|
AI Committee View
Current Innellis committee reasoning for ASND versus VRTX.
The committee scores are tied.
ASND and VRTX both score 66/100.
ASND Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 129.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 134.8% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 27.9 is moderate-to-rich — Value
- Price-to-book of 22.5x prices in significant intangible value — Value
- Debt-to-equity of 1.93 adds balance-sheet risk to the value case — Value
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical